Life Science News

RSS

NRC helps Olympus to design and commercialize CARS microscope

The National Research Council Canada (NRC) recently helped Olympus, a world leader in advanced optical microscopy and medical imaging, to design and commercialize a CARS (Coherent Anti-stokes Raman Scattering) microscope.

From Olympus Life Science Solutions 16 Nov 2009

New microplate for BioFlux live cell imaging workstations

Fluxion Biosciences introduces a new microplate for its BioFlux live cell imaging workstations, extending their shear flow limits to simulate a variety of pathological vascular conditions. With the new High Shear Plate, the BioFlux systems can be an effective tool in thrombosis and platelet studies, cardiovascular and immunological drug screening and cell/bacteria adhesion research.

From Fluxion Biosciences 11 Nov 2009

World's smallest gastrointestinal videoscope with four-way angulation and NBI

Olympus today introduced the world's smallest gastrointestinal videoscope to offer four-way angulation and Narrow Band Imaging™ (NBI) to detect upper gastrointestinal abnormalities. The super-slim scope is 5.5 mm in diameter at the distal end, as well as the insertion tube, and offers exceptional insertion capability to enhance patient comfort. The scope also features NBI, Olympus' proprietary imaging technology that filters white light to consist of specific wavelength bands enabling enhanced observation of microvessels and subtle changes on the mucosa.

From Olympus Life Science Solutions 11 Nov 2009

Olympus Medical Systems and Opitz + Flierl Hospitaltechnik offer complete integrated solutions for operating theatres

Under the leadership of its Systems Integration business unit, Olympus Medical Systems Europa GmbH, Hamburg, together with Opitz + Flierl Hospitaltechnik AG, Heideck near Nuremberg, Germany, have agreed a joint venture to meet the technological challenges of constructing hospital interiors for the future, whilst expanding their positions in the market.

From Olympus Life Science Solutions 9 Nov 2009

$1.85 million grant to study how digital games can improve players' health behaviors and outcomes

The Robert Wood Johnson Foundation (RWJF) today announced more than $1.85 million in grants for research that will offer unprecedented insight into how digital games can improve players' health behaviors and outcomes. With funding from RWJF's Health Games Research national program, nine research teams across the country will conduct extensive studies to discover, for example, how the popular dance pad video game Dance Dance Revolution might help Parkinson's patients reduce the risk of falling, how Wii Active might be most effectively implemented in high schools to help overweight students lose weight, how a mobile phone game with a breath interface might help smokers quit or reduce their tobacco use, or how facial recognition games might be designed to help people with autism learn to identify others' emotions.

From Olympus Life Science Solutions 6 Nov 2009

PerkinElmer receives FDA clearance for its Genetic Screening Processor

PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced that the Company has received 510K clearance from the U.S. Food and Drug Administration for its GSP™ Genetic Screening Processor, which is used by public health laboratories worldwide as part of newborn screening programs.

From PerkinElmer 4 Nov 2009

PerkinElmer and Corning collaborate in development of label-free detection technologies

PerkinElmer Inc. and Corning Incorporated, today announced that the two companies have entered into a strategic agreement to advance the development of next-generation label-free detection technologies.

From PerkinElmer 28 Oct 2009

Thermo Fisher Scientific announces the availability of its Copeptin assay in Europe

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the availability in Europe of its new Copeptin assay, which helps medical personnel quickly and accurately diagnose acute myocardial infarction (AMI), commonly known as a heart attack.

From Thermo Fisher Scientific Inc. 26 Oct 2009

New nucleic acid test to screen donated blood for HIV-1 Group M RNA approved

Health Canada has approved a new nucleic acid test from Roche Diagnostics to screen donated blood for HIV-1 Group M RNA, hepatitis C RNA and hepatitis B DNA in a single, automated assay.

From Roche Diagnostics Limited 24 Oct 2009

AOTI to incorporate PerkinElmer’s GC products to enhance measurement applications

PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, has entered into a resale arrangement with Alpha Omega Technologies Inc. (AOTI).

From PerkinElmer 24 Oct 2009

Olympus introduces Endo Capsule Software for examining high resolution small bowel images

Olympus, a precision technology leader, creating innovative opto-digital solutions in healthcare, life science and consumer electronics products, today announced the introduction of its improved user-friendly Endo Capsule Software version 1.02A, a customized and comprehensive system for examining high resolution small bowel images.

From Olympus Life Science Solutions 24 Oct 2009

Thermo Fisher Scientific's revenues decrease by 2% in third quarter 2009

Thermo Fisher Scientific Inc., the world leader in serving science, reported that revenues decreased 2% to $2.53 billion in the third quarter of 2009, compared with $2.59 billion in the 2008 quarter. These results reflect the impact of foreign currency translation, which lowered revenues by 2%, and acquisitions, which increased revenues by 2%. GAAP diluted earnings per share (EPS) were $.53 in 2009, versus $.50 in the year-ago period. GAAP operating income for the 2009 quarter was $275 million, compared with $286 million in 2008, and GAAP operating margin was 10.9%, compared with 11.1% a year ago.

From Thermo Fisher Scientific Inc. 22 Oct 2009

New LANCE Ultra assay products to detect and analyze protein kinase activity

PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, announced that it has expanded the industry’s largest reagent product portfolio for the detection and analysis of protein kinase activity to 310 assays.

From PerkinElmer 20 Oct 2009

New Enspire Multilabel Plate Reader platform from PerkinElmer

PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today launched the latest expansion of the EnSpire™ Multilabel Plate Reader platform ─ EnSpire, with ultra sensitive luminescence detection.

From PerkinElmer 20 Oct 2009

Olympus unveils new surgical instruments for single-incision procedures

Olympus, a precision technology leader, creating innovative opto-digital solutions in healthcare, life science and consumer electronics products, today introduced three new surgical instruments specifically designed for Laparo-Endoscopic Single-Site (LESS) surgery

From Olympus Life Science Solutions 19 Oct 2009

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems.

From Ortho-Clinical Diagnostics, Inc. 15 Oct 2009

Affymetrix unveils Axiom Genotyping Solution

Affymetrix, Inc. today announced the launch of the Axiom Genotyping Solution, its next-generation array technology designed to match the significant rise in genetic content generated by government and privately funded sequencing projects. This high-throughput, automated platform enables researchers to find novel genetic variations associated with complex disease.

From Beckman Coulter Life Sciences - Automation and Genomics 15 Oct 2009

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).

From Thermo Fisher Scientific Inc. 3 Oct 2009

SAIC-Frederick and Roche collaborate on technology advancements in sequencing cancer genes

National Cancer Institute contractor SAIC-Frederick, Inc., a wholly owned subsidiary of Science Applications International Corporation, and Roche Applied Science, a division of Roche Diagnostics Corporation, have signed a collaboration agreement to assess Roche’s advanced technologies to sequence the genomes of cancer research samples.

From Roche Diagnostics Limited 29 Sep 2009

PerkinElmer launches DSC-Raman spectroscopy hyphenated system

PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, has emerged as a leader in hyphenated scientific instrumentation with the launch of its exclusive Differential Scanning Calorimetry (DSC)-Raman spectroscopy hyphenated system.

From PerkinElmer 29 Sep 2009